Cytocidal agent

Abstract

The present invention is a cytocidal agent including a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 and a site selectively binding to a target molecule, in which the peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 is a peptide exclusively consisting of L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to the 14th amino acids are D-amino acids, and the 15th to 19th amino acids are L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to 14th amino acids are L-amino acids, and the 15th to the 19th amino acids are D-amino acids, or a peptide exclusively consisting of D-amino acids.

1 - 10 . (canceled) 
     
     
         11 . A method of determining a disease onset possibility of a disease in which disease-causing cells have expressed CNGB3 and treating the disease, comprising:
 measuring CNGB3 in an exosome collected from a subject animal;   comparing the obtained measurement value with a pre-set reference value to determine a possibility that the subject animal has developed the disease; and   treating the disease with an effective amount of a compound indicated for treating the disease, wherein   the disease is cancer.   
     
     
         12 . The method according to  claim 11 , wherein
 determining that the subject animal has a high possibility of developing the disease if the measurement value exceeds the reference value.   
     
     
         13 . The method according to  claim 11 , wherein the exosome is isolated from blood collected from the subject animal. 
     
     
         14 . The method according to  claim 11 , wherein
 measuring CNGB3 by using a peptide consisting of an amino acid sequence represented by SEQ ID NO: 2.   
     
     
         15 . The method according to  claim 11 , wherein the subject animal is a human. 
     
     
         16 . (canceled) 
     
     
         17 . A biomarker used for determining presence or absence of disease onset of endometriosis or cancer, comprising:
 an amount of CNGB3 in an exosome.